Progressive supranuclear palsy (PSP) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Progressive supranuclear palsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Progressive supranuclear palsy from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2030
Progressive supranuclear palsy - Disease Understanding and Treatment Algorithm
Progressive Supranuclear Palsy (PSP, Steele-Richardson-Olszewski syndrome) is a sporadic, progressive, neurodegenerative disease clinically resulting in a symmetrical Parkinson syndrome, prominent postural instability with falls, a vertical gaze palsy and a cognitive decline. Progressive supranuclear palsy is characterized pathologically by four-repeat (4R) Tau deposition in various cell types and anatomical regions. The broad spectrum of syndromes that has been linked to PSP pathology also includes PSP-parkinsonism, a variant that presents with features suggestive of Parkinson's disease (PD), pure akinesia with gait freezing, corticobasal syndrome, non-fluent variant primary progressive aphasia, behavioural variant frontotemporal dementia and even PSP presenting with cerebellar ataxia.The most frequent comorbidities in PSP patients were nervous system disorders, connective tissue diseases, eye disorders, and non-traumatic joint disorders. At present, therapeutic options for PSP are symptomatic and insufficient. PSP symptoms usually do not respond to medications. Recent approaches to therapeutic development for PSP have focused primarily on the clearance of abnormally accumulated tau in the brain.
The Progressive supranuclear palsy market report gives the thorough understanding of the Progressive supranuclear palsy by including details such as disease definition, classification, symptoms, etiology, associated risk factors, pathophysiology, clinical features and diagnostic trends. It also provides treatment algorithms and management approaches for Progressive supranuclear palsy in the US, Europe and Japan.
Progressive supranuclear palsy Epidemiology
The Progressive supranuclear palsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalence of Progressive supranuclear palsy, Phenotype associated with Progressive supranuclear palsy, Gender specific Prevalence of Progressive supranuclear palsy, Comorbidities associated with Progressive supranuclear palsy) scenario of Progressive supranuclear palsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
According to the publisher estimate, there were 98,498 cases of Progressive supranuclear palsy in 7MM in 2017.
Progressive supranuclear palsy Drug Chapters
This segment of the Progressive supranuclear palsy report encloses the detailed analysis of pipeline drugs (Phase-I and Phase-II). It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, there is no disease-modifying treatment for PSP. The aim of existing treatments is symptomatic. While there is currently no disease modifying therapy for PSP, some treatment strategies have been successful for symptomatic management. There is typically a poor response to levodopa in PSPRS patients. However, some patients with the PSP-P phenotype may show moderate motor improvement with levodopa for the first 2-3 years. Dopamine agonists and amantadine have also been observed to provide benefit in a few PSP-P patients during the early years. Other supportive approaches involve use of Botulinum toxin and Rivastigmine.
Progressive supranuclear palsy Market Outlook
The Progressive supranuclear palsy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the market of Progressive supranuclear palsy in 7MM was found to be USD 10.54 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of Progressive supranuclear palsy , in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Progressive supranuclear palsy Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Progressive supranuclear palsy Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Progressive supranuclear palsy Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Key Cross Competition
- Market Size by Therapies
- Drugs Uptake
Progressive supranuclear palsy Report Assessment
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
- This report will help to develop Business Strategies by understanding the trends shaping and driving Progressive supranuclear palsy market
- Organize sales and marketing efforts by identifying the best opportunities for Progressive supranuclear palsy market
- To understand the future market competition in the Progressive supranuclear palsy market.
Table of Contents
4.2 Market Share (%) Distribution of Progressive Supranuclear Palsy (PSP) in 2030
5.2 Signs and symptoms
5.3 Phenotypes of Progressive Supranuclear Palsy
5.5 Associated risk factors
5.8 PSP associated abnormalities
5.9 Clinical Presentation and Assessment
5.1 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria
5.11 PET Imaging as a Biomarker in Tauopathies
6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]
7.1.1 Assumptions and Rationale
7.1.2 Total Prevalent Patient Population of PSP in the United States
7.1.3 Phenotype associated with PSP in the United States
7.1.4 Gender specific Prevalence of PSP in the United States
7.1.5 Comorbidities associated with PSP in the United States
7.2.1 Assumptions and Rationale
22.214.171.124 Total Prevalent Patient Population of PSP in Germany
126.96.36.199 Phenotype associated with PSP in Germany
188.8.131.52 Gender specific Prevalence of PSP in Germany
184.108.40.206 Comorbidities associated with PSP in Germany
220.127.116.11 Total Prevalent Patient Population of PSP in France
18.104.22.168 Phenotype associated with PSP in France
22.214.171.124 Gender specific Prevalence of PSP in France
126.96.36.199 Comorbidities associated with PSP in France
188.8.131.52 Total Prevalent Patient Population of PSP in Italy
184.108.40.206 Phenotype associated with PSP in Italy
220.127.116.11 Gender specific Prevalence of PSP in Italy
18.104.22.168 Comorbidities associated with PSP in Italy
22.214.171.124 Total Prevalent Patient Population of PSP in Spain
126.96.36.199 Phenotype associated with PSP in Spain
188.8.131.52 Gender specific Prevalence of PSP in Spain
184.108.40.206 Comorbidities associated with PSP in Spain
7.2.6 The United Kingdom
220.127.116.11 Total Prevalent Patient Population of PSP in the United Kingdom
18.104.22.168 Phenotype associated with PSP in the United Kingdom
22.214.171.124 Gender specific Prevalence of PSP in the United Kingdom
126.96.36.199 Comorbidities associated with PSP in the United Kingdom
7.3.1 Assumptions and Rationale
7.3.2 Total Prevalent Patient Population of PSP in Japan
7.3.3 Phenotype associated with PSP in Japan
7.3.4 Gender specific Prevalence of PSP in Japan
7.3.5 Comorbidities associated with PSP in Japan
10.1.1 Product Description
10.1.2 Other Development Activities
10.1.3 Clinical Development
10.1.3.1 Clinical Trials Information
10.1.4 Safety and efficacy
10.2 UCB0107: UCB Biopharma
10.2.1 Product Description
10.2.2 Clinical Development
10.2.2.1 Clinical Trials Information
10.2.3 Safety and efficacy
10.3 ASN 120290: Asceneuron
10.3.1 Product Description
10.3.2 Other Development Activities
10.3.3 Clinical Development
10.3.4 Safety and efficacy
10.4 RT001: Retrotope
10.4.1 Product Description
10.4.2 Other Development Activities
11.2 Total Market Size of PSP in 7MM
11.3 Market Outlook: 7MM
12.2 PSP Market Size by Therapies
13.1.1 Total Market size of PSP
13.1.2 PSP Market Size by Therapies
13.2.1 Total Market size of PSP
13.2.2 PSP Market Size by Therapies
13.3.1 Total Market size of PSP
13.3.2 PSP Market Size by Therapies
13.4.1 Total Market size of PSP
13.4.2 PSP Market Size by Therapies
13.5 United Kingdom
13.5.1 Total Market size of PSP
13.5.2 PSP Market Size by Therapies
14.2 PSP Market Size by Therapies
A selection of companies mentioned in this report includes:
- UCB Biopharma